Corn Benjamin W, Wexler Isaiah D, Suntharalingam Mohan, Inbar Moshe, Curran Walter J
Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel.
J Clin Oncol. 2008 Mar 1;26(7):1160-6. doi: 10.1200/JCO.2007.14.3891.
The Radiation Therapy Oncology Group (RTOG) is part of the cooperative group network that is overseen by the National Cancer Institute (NCI). Although the NCI is a US-based group, it has empowered the cooperative groups to recruit foreign institutions to participate in collaborative clinical trials. The RTOG undertook the challenge of globalizing its efforts in 2004. This article describes the rationale for this decision and the tactics adopted by the first hospital outside of North America to enroll patients onto RTOG trials. The challenges confronted by foreign institutions seeking admission to the RTOG and the mechanism by which Tel Aviv Medical Center (TAMC) met these challenges are described. Shortly after its acceptance, TAMC emerged as one of the leading accruers of patients to RTOG studies. The public health implications of this accomplishment are discussed.
放射治疗肿瘤学组（RTOG）是由美国国立癌症研究所（NCI）监管的合作组网络的一部分。尽管NCI是一个总部设在美国的组织，但它已授权各合作组招募外国机构参与协作性临床试验。RTOG在2004年接受了将其工作全球化的挑战。本文描述了这一决定的基本原理，以及北美以外第一家医院将患者纳入RTOG试验所采用的策略。阐述了寻求加入RTOG的外国机构所面临的挑战，以及特拉维夫医疗中心（TAMC）应对这些挑战的机制。在被接纳后不久，TAMC就成为了RTOG研究中患者招募量领先的机构之一。本文还讨论了这一成就对公共卫生的影响。
